Reference : Natalizumab induces a rapid improvement of disability status and ambulation after fai...
Scientific journals : Article
Human health sciences : Neurology
http://hdl.handle.net/2268/75170
Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.
English
Belachew, Shibeshih mailto [Université de Liège - ULg > Département des sciences cliniques > Neurologie >]
Phan-Ba, Rémy [Université de Liège - ULg > Département des sciences cliniques > Département des sciences cliniques >]
Bartholome, Emmanuel [C.H.U. Tivoli, La Louvière > Neurologie > > >]
Delvaux, Valérie [Centre Hospitalier Universitaire de Liège - CHU > > Neurologie Sart Tilman >]
Hansen, Isabelle [Centre Hospitalier Universitaire de Liège - CHU > > Neurologie Sart Tilman >]
Calay, Philippe [Centre Hospitalier Universitaire de Liège - CHU > > Neurologie Sart Tilman >]
El Hafsi, Kaoutar [Cliniques Universitaires de Bruxelles - Hôpital Erasme > Neurologie > > >]
Moonen, Gustave [Centre Hospitalier Universitaire de Liège - CHU > > Neurologie Sart Tilman >]
Tshibanda, Luaba [Centre Hospitalier Universitaire de Liège - CHU > > Imagerie médicale >]
Vokaer, Mathieu [Cliniques Universitaires de Bruxelles - Hôpital Erasme > Neurologie > > >]
Feb-2010
European Journal of Neurology
Blackwell Science
18
2
240-245.
Yes (verified by ORBi)
International
1351-5101
1468-1331
Oxford
United Kingdom
[en] Background: Natalizumab (Tysabri) is a monoclonal antibody that was recently approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Our primary objective was to analyse the efficacy of natalizumab on disability status and ambulation after switching patients with RRMS from other disease-modifying treatments (DMTs). Methods: A retrospective, observational study was carried out. All patients (n = 45) initiated natalizumab after experiencing at least 1 relapse in the previous year under interferon-beta (IFNB) or glatiramer acetate (GA) treatments. The patients also had at least 1 gadolinium-enhancing (Gd+) lesion on their baseline brain MRI. Expanded Disability Status Scale (EDSS) scores, and performance on the Timed 25-Foot Walk Test and on the Timed 100-Metre Walk Test were prospectively collected every 4 weeks during 44 weeks of natalizumab treatment. Brain MRI scans were performed after 20 and 44 weeks of treatment. Results: Sixty-two per cent of patients showed no clinical and no radiological signs of disease activity, and 29% showed a rapid and confirmed EDSS improvement over 44 weeks of natalizumab therapy. Patients with improvement on the EDSS showed similar levels of baseline EDSS and active T1 lesions, but had a significantly higher number of relapses, and 92% of them had experienced relapse-mediated sustained EDSS worsening in the previous year. A clinically meaningful improvement in ambulation speed was observed in approximately 30% of patients. Conclusions: These results indicate that natalizumab silences disease activity and rapidly improves disability status and walking performance, possibly through delayed relapse recovery in patients with RRMS who had shown a high level of disease activity under other DMTs.
http://hdl.handle.net/2268/75170
10.1111/j.1468-1331.2010.03112.x

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Belachew EJN 2010.pdfPublisher postprint386.33 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.